Business
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in
About this update from Bioxcel Therapeutics, Inc.
[{"type":"image","alt":"BioXcel Therapeutics","displaySize":"","headline":null,"caption":"BioXcel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":220,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ugin_5Up8vRFuzpQTrOKug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87","width":220,"height":123}},"lazy":false},{"type":"text","content":"Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer","length":75,"tagName":"p"},{"type":"text","content":"Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026","length":152,"tagName":"p"},{"type":"text","content":"BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month","length":69,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 30 years of experience with well-known CNS products, has joined as Acting Chief Commercial Officer and will lead the development and execution of the Company's commercial plans. The Company plans to submit a supplemental New Drug Application (sNDA) this month seeking the FDA’s approval of IGALMI for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.","length":805,"tagName":"p"},{"type":"text","content":"“We are taking important steps in planning and solidifying our optionality for the potential launch of IGALMI for at-home use,” said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. “Mark brings enormous experience in CNS drug launches and brand building, which will enable us to determine the best approaches to commercializing this important treatment option and maximizing the value of the IGALMI franchise. We remain focused on how to best provide greater access and convenience to patients ...